Background Endovascular coiling has become a routine modality for intracranial aneurysms. Scientific reports on the safety and feasibility of the Optima and OptiMAX coil system (Balt USA, LLC) are scarce in the neuro-interventional literature. We here report the first US experience of the early safety and outcome of using the Optima and OptiMAX coil system.
Objective To report our single-center experience with Optima and OptiMAX Coil system in a series of consecutive patients having different neuroendovascular procedures
Methods A retrospective, single-center analysis of an IRB-approved and prospectively maintained database was conducted. Patients between October 2020 and February 2023 undergoing neuroendovascular procedures with Optima and OptiMAX coil system were included. A total of 20 patients were involved in our series. Patient demographics, procedural details, Angiographic parameters, periprocedural complications, and Angiographic and clinical follow-up information were collected.
Results A total of 20 patients were included. 70% (14/20) were females. The mean patient age was 53.55 ± 22.19 years. Of the patients treated 85% (17/20) were intracranial aneurysms (IA), 10% (2/20) were arteriovenous fistula (AVF), and 5% (1/20) were arteriovenous malformation (AVM). Of the aneurysmal cases, 5 patients presented with ruptured aneurysms. The majority of the aneurysms were located in the ICA (n= 11). The mean aneurysmal diameter was 6.72 ± 2.34. Coil system deployment was successful in all cases (n= 20). No Optima or OptiMAX Coils-related complications or adverse events were encountered. Complete aneurysmal obliteration, measured as Raymond- Roy class 1, was achieved in (n= 13) cases. Of the ruptured aneurysmal cases, (n=3) patients achieved Raymond Roy Class 2, and (n=1) achieved Raymond Roy class 3. On Follow-up, none of the patients showed aneurysmal recanalization or required retreatment.
Conclusion Our early single-center experience demonstrates that Optima and OptiMAX Coil system is associated with high technical success and early safety profile in various neurovascular pathologies. A prospective, multicentric, and large sample size with long-term follow-up is warranted to confirm the findings of our study.
Optima, OptiMAX, Coils, Embolization, Intracranial aneurysms
Disclosures A. Abdelsalam: None. H. Fountain: None. M. Knott: None. M. Costello: None. T. Eatz: None. M. Silva: None. E. Wu: None. R. Starke: 1; C; Balt.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.